Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Brisebois is a 3-star analyst with an average return of 2.4% and a 40.11% success rate. Brisebois covers the Healthcare sector, focusing on stocks such as Savara, Praxis Precision Medicines, and Opus Genetics.
In addition to LifeSci Capital, Dyne Therapeutics also received a Buy from Evercore ISI’s Gavin Clark-Gartner in a report issued yesterday. However, on May 13, Bernstein assigned a Hold rating to Dyne Therapeutics (NASDAQ: DYN).
Based on Dyne Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $120.85 million. In comparison, last year the company had a GAAP net loss of $115.36 million
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of DYN in relation to earlier this year. Last month, Brian S. Posner, a Director at DYN bought 2,000.00 shares for a total of $34,160.00.
